Ara S. Khachaturian, Ph.D.

Ara S. Khachaturian, Ph.D., is an accomplished and experienced leader in public health policy. With over twenty years of expertise in complex computer modeling and epidemiological and clinical research, including specialized knowledge in population and clinical biomedical research, public health policy, and public finance, he continues to serve as Executive Vice-President of Prevent Alzheimer’s 2020, Inc., as well as founding Executive Editor of the esteemed journals Alzheimer’s & Dementia, Alzheimer’s & Dementia: Diagnosis, Assessment and Disease Monitoring, and Alzheimer’s & Dementia: Translation Research & Clinical Interventions. He is also a Senior Research Fellow at the National Supercomputing Institute of the University of Nevada at Las Vegas. Having studied psychiatric epidemiology with a concentration in biostatistics at the renowned Bloomberg School of Public Health at Johns Hopkins University, Dr. Khachaturian received his undergraduate degree in econometrics from Pennsylvania State University — all testament to his admirable academic achievements. Dr. Khachaturian is an exemplary professional whose knowledge and skills are invaluable to his field.

Zaven S. Khachaturian, ph.d.

Dr. Zaven S. Khachaturian is a distinguished and renowned leader in the medical field and an expert in Alzheimer’s research. He has made remarkable contributions to his field, having earned both a Bachelor of Science from Yale and a Ph.D. from Case Western Reserve University; he is the President of Prevent Alzheimer’s Disease 2020, Inc., an Adjunct Professor of Psychiatry and Neuroscience, Division of Geriatric Psychiatry at Johns Hopkins School of Medicine, as well as the founding Editor-in-Chief of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Dr. Khachaturian’s outstanding work has received many honors, such as the NIH Director’s Award from the National Institutes of Health and the Department of Health and Human Services Senior Executive Service Award. His dedication to advancing neurological research has earned him recognition as the “father of Alzheimer’s research in the United States” by the Alzheimer’s Association’s President’s Award. He is truly a remarkable individual who has extensively impacted neuroscience research worldwide!

brittany cassin, m.b.a.

Brittany Cassin is the Chief Executive Officer, and Co-Founder of DigiCARE Realized, an emerging artificial intelligence and health technology firm focused on modernizing care in complex brain disease through decision intelligence applications.  DigiCARE Realized is founded on technology developed at Indiana University.

With more than 20 years of work in healthcare commercialization, Brittany’s health technology product experience includes the first-ever digital medicine system approved by the FDA in 2017.

She has also successfully led health system partnerships that include research collaborations for pragmatic trials in both serious mental illness and Alzheimer’s disease and related dementia for various regulated digital technologies.  In a previous role, Brittany was the US business lead for an FDA-cleared digital cognitive assessment tool focused on early-stage Alzheimer’s disease detection. As a female Hispanic founder, Brittany was named a 2022 finalist to the inaugural cohort of the National Institute of Aging (NIA) Start-Up Challenge and Accelerator: Fostering Entrepreneurial Diversity.  She also serves as a member of the CEOi Blood-Based Bio-Marker Workgroup and is a collaborator to the Davos Alzheimer’s Collaborative – System Preparedness Workgroup: Early Detection of Cognitive Impairment.

Drew Holzapfel, m.b.a.

Drew Holzapfel is a Partner at High Lantern Group, having opened offices for the firm in Philadelphia and Geneva, Switzerland. He joined High Lantern Group from Pfizer, where he led aspects of the global commercial development for its Alzheimer’s program. In this role, he led numerous efforts to advance Alzheimer’s and aging issues. A former Special Assistant to the Secretary of the U.S. Department of Health and Human Services in the Clinton Administration. He has led the development of ReACT (, a coalition of Fortune 500 companies seeking to support better employees serving as caregivers, which was launched at the World Economic Forum in 2010. Additionally, he participated in the creation of the CEO Initiative on Alzheimer’s Disease, a business coalition focused on improving Alzheimer’s research and development, diagnosis and treatment, and raising awareness of the disease.

Blog at